Search

Displaying results 3611 - 3620 of 5895 in total
  1. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development.

  2. Drug

    KB109

    go.drugbank.com/drugs/DB16531
    Experimental

    KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.

  3. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    wild type human G-CSF to avoid PEGylation of such sites. … This was accomplished by removing the three lysine residues at positions 16, 34 and 40, and replacing them with arginine, and substituting two new lysine residues at positions 105 and 159.

  4. Drug

    rhMBL

    go.drugbank.com/drugs/DB05237
    Investigational

    MBL forms different oligomers but must form at least a tetramer to be active. … Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains.

  5. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.

  6. Drug

    Anti-SARS-CoV-2 immunoglobulin

    go.drugbank.com/drugs/DB16360
    Investigational

    Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies.

    Synonyms: Hyperimmune immunoglobulin to SARS-CoV-2
  7. Drug

    Perospirone

    go.drugbank.com/drugs/DB08922
    Investigational

    It is also shown to be less associated with extrapyramidal symptoms as a side effect compared to [DB00502]. … Classified as a neuroleptic agent, perospirone is shown to be effective against positive, negative and general symptoms in patients with schizophrenia [A19676].

  8. Drug

    Etoricoxib

    go.drugbank.com/drugs/DB01628
    ApprovedInvestigationalWithdrawn

    Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid.

    Products: ETORICOXIB DOC GENERICI, ETORICOXIB GENERIC PARTNERS
  9. Drug

    Desoxyribonuclease

    go.drugbank.com/drugs/DB09551
    ApprovedInvestigational

    The enzyme's cofactor is reported to be magnesium (or manganese) ions, although the optimal concentration of the ion is independent of the enzyme concentration [A31251].

  10. Drug

    Nevadistinel

    go.drugbank.com/drugs/DB21632
    Investigational

    The usage of the INN stem '-stinel' in the name indicates that Nevadistinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist. … Nevadistinel is under investigation in clinical trial NCT04148391 (NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory